• Gastrin I Peptide: Precision Tools for Gastric Acid Pathway

  2026-06-28

  Harness the specificity of human Gastrin I peptide for advanced modeling of gastric acid secretion and CCK2 receptor signaling. This guide delivers actionable workflows, troubleshooting insights, and practical enhancements for gastrointestinal physiology studies, especially in hiPSC-derived organoid systems.

• FK866 (APO866): Precision NAMPT Inhibition in AML Research

  2026-06-27

  FK866 (APO866) enables highly selective NAD depletion and caspase-independent cell death in hematologic cancer models, offering protocol-driven advantages for both metabolic and immunological research. This guide distills evidence-backed workflows, troubleshooting, and cross-domain insights for AML and host-pathogen studies.

• KDM3A/METTL16-Driven PDK1 Upregulation Mediates TKI Resistan

  2026-06-26

  This study uncovers a novel epigenetic axis—KDM3A/METTL16/PDK1—that drives resistance to EGFR tyrosine kinase inhibitors (TKIs) in cancer. By linking histone and mRNA modifications to PDK1 overexpression, the research offers new biomarkers and therapeutic targets for overcoming TKI resistance.

• Caspase-3 and ERO1α Drive Trichothecene-Induced Liver ROS Ac

  2026-06-26

  This study delineates a mechanistic axis in which caspase-3-mediated cleavage of mitochondrial NDUFS1 and ER-localized ERO1α synergistically amplify reactive oxygen species (ROS) in liver cells exposed to trichothecene mycotoxins. The findings clarify the molecular basis of toxin-induced mitochondrial dysfunction, revealing new targets for mitigating hepatotoxicity.

• Rotigotine Hydrochloride: Dopamine D2/D3 Agonist in PD Model

  2026-06-25

  Rotigotine hydrochloride stands out as a full dopamine D2/D3 receptor agonist, enabling robust modeling of Parkinson’s disease, depression, and neuroprotection in both in vitro and in vivo settings. This guide demystifies protocol enhancements, highlights experimental innovations, and delivers practical troubleshooting tips for high-impact dopaminergic research.

• Analytical Advances for Rotigotine Hydrochloride in PD Resea

  2026-06-25

  This review systematically evaluates analytical methodologies for assessing rotigotine, a dopamine D2/D3 receptor agonist, in raw materials and transdermal formulations, with a particular focus on impurity profiling and stability. The work advances quality control protocols essential for the safe and effective use of rotigotine in Parkinson’s disease research and therapy.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-06-24

  Schwartz's dissertation presents a detailed evaluation of how anti-cancer drugs impact both proliferation and cell death in vitro, challenging the interchangeable use of relative and fractional viability metrics. By dissecting these response parameters, the work provides oncology researchers with more accurate tools for assessing tyrosine kinase inhibitors and other targeted agents.

• Intestinal TM6SF2 Deficiency Drives MASH via Gut–Liver Axis

  2026-06-23

  The referenced Nature Metabolism study uncovers how intestinal TM6SF2 protects against metabolic dysfunction-associated steatohepatitis (MASH) by maintaining gut barrier function and regulating host–microbe interactions. These findings highlight the gut–liver axis, lipid signaling, and the LPA pathway as critical mechanisms and therapeutic targets for MASH intervention.

• Remdesivir (GS-5734): Strategic Advances in Antiviral Transl

  2026-06-23

  This thought-leadership article delivers a mechanistic and strategic roadmap for translational researchers leveraging Remdesivir (GS-5734) in the fight against RNA viruses. By synthesizing recent structural breakthroughs, comparative evidence, and practical guidance, we chart new territory beyond conventional product narratives—empowering virology innovation at the bench and translational interface.

• HATU: Benchmark Peptide Coupling Reagent for Amide Formation

  2026-06-22

  HATU (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate) is a gold-standard peptide coupling reagent enabling rapid, high-yield amide and ester bond formation. Its mechanism relies on carboxylic acid activation to OAt-active esters, which increases nucleophilic reactivity and selectivity in peptide synthesis chemistry. Robust protocols, broad literature support, and predictable performance make HATU essential for modern biochemical and pharmaceutical workflows.

• Cy3 NHS ester (non-sulfonated): Protocols, QC, and Limitatio

  2026-06-22

  Cy3 NHS ester (non-sulfonated) enables sensitive, high-contrast labeling of proteins, peptides, and oligonucleotides for imaging and quantitative assays, especially when water solubility is not required. Its use is best suited to workflows accommodating organic co-solvents (DMSO/DMF), but it is less appropriate for highly sensitive or labile biomolecules due to potential denaturation risks from these solvents.

• 3D Spheroid Cultures as Patient-Derived Models for Prostate

  2026-06-21

  This study establishes patient-derived, three-dimensional spheroid cultures from radical prostatectomy specimens as a robust in vitro model for organ-confined prostate cancer. The work demonstrates the system's utility for drug testing and microenvironment analysis, offering new avenues for translational cancer research.

• S Tag Peptide: Technical Guidance for Solubility & Detection

  2026-06-20

  S Tag Peptide addresses challenges in recombinant protein detection and solubility by serving as a highly soluble fusion tag for affinity-based purification and antibody-mediated assays. It is best used in workflows requiring robust anti-S-Tag antibody detection or protein solubility improvement, but should not be applied in ethanol-based protocols or as an independently active enzyme fragment.

• PRV Activates TLR-NF-κB and AIM2 Inflammasome for Inflammato

  2026-06-19

  This study demonstrates that pseudorabies virus (PRV) infection robustly activates the TLR-NF-κB signaling axis and the AIM2 inflammasome, driving pro-inflammatory cytokine release in mice. These insights clarify how PRV manipulates innate immune pathways and provide novel directions for inflammation research and antiviral intervention.

• Tacalcitol Monohydrate: Bridging Dermatology and Oncology Fr

  2026-06-19

  This thought-leadership article explores Tacalcitol monohydrate’s unique mechanistic profile as a synthetic analog of vitamin D3, highlighting its dual promise in dermatological and oncological research. Integrating evidence from recent studies, including its synergistic enhancement of 5-fluorouracil’s anticancer activity and its transcriptional induction of nerve growth factor, we provide translational researchers with strategic guidance for experimental design and clinical application. The article situates Tacalcitol monohydrate within the evolving landscape of vitamin D analogs, addresses protocol optimization, and delineates key considerations for realizing its full potential from bench to bedside.

449 records 13/30 page Previous Next First page 上5页 1112131415 下5页 Last page